Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CFO Hunter C. Smith Sells 1,296 Shares

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CFO Hunter C. Smith sold 1,296 shares of the company’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $57.51, for a total transaction of $74,532.96. Following the completion of the transaction, the chief financial officer now directly owns 106,295 shares in the company, valued at approximately $6,113,025.45. The trade was a 1.20 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Rhythm Pharmaceuticals Stock Down 1.5 %

Shares of Rhythm Pharmaceuticals stock traded down $0.89 during trading on Tuesday, reaching $57.58. 289,541 shares of the stock were exchanged, compared to its average volume of 495,983. The stock’s fifty day moving average is $57.22 and its 200 day moving average is $53.42. The firm has a market cap of $3.54 billion, a price-to-earnings ratio of -13.30 and a beta of 2.14. Rhythm Pharmaceuticals, Inc. has a 1 year low of $35.17 and a 1 year high of $68.58.

Institutional Trading of Rhythm Pharmaceuticals

Institutional investors have recently modified their holdings of the company. SRS Capital Advisors Inc. boosted its holdings in shares of Rhythm Pharmaceuticals by 740.7% during the fourth quarter. SRS Capital Advisors Inc. now owns 454 shares of the company’s stock worth $25,000 after purchasing an additional 400 shares during the period. Raleigh Capital Management Inc. purchased a new stake in shares of Rhythm Pharmaceuticals during the fourth quarter worth about $28,000. SBI Securities Co. Ltd. purchased a new stake in Rhythm Pharmaceuticals in the fourth quarter worth about $37,000. R Squared Ltd purchased a new stake in Rhythm Pharmaceuticals in the fourth quarter worth about $44,000. Finally, ORG Wealth Partners LLC purchased a new stake in Rhythm Pharmaceuticals in the third quarter worth about $63,000.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Guggenheim assumed coverage on Rhythm Pharmaceuticals in a research note on Monday, October 21st. They issued a “buy” rating and a $70.00 target price on the stock. Canaccord Genuity Group reissued a “buy” rating and issued a $80.00 target price on shares of Rhythm Pharmaceuticals in a research note on Tuesday, November 19th. HC Wainwright reissued a “buy” rating and issued a $69.00 target price on shares of Rhythm Pharmaceuticals in a research note on Monday, December 23rd. JMP Securities reissued a “market outperform” rating and issued a $75.00 target price on shares of Rhythm Pharmaceuticals in a research note on Monday, December 23rd. Finally, Oppenheimer assumed coverage on Rhythm Pharmaceuticals in a research note on Friday, December 20th. They issued an “outperform” rating and a $76.00 target price on the stock. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $68.09.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.